Fundamental Analysis of Novo Nordisk A/S - Growth / Value Index
NVO - Valuation Highlights
Valuation Analysis
Tsr Value Index - Excellent Score of 81.25
Undervalued - Price to Intrinsic Value of 0.0217
Price to Earning Ratio is 6.68 and EV to EBITDA is 4.87 suggesting company is undervalued.
Tremendous increasing in Book Value last 3 year
Price to Book Ratio of 6.36 suggesting that it is very expensive
Valuation Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Price to Earning | 6.63 | 7.08 | -34.38 % | |
Price to Book | 6.31 | 5.56 | -22.51 % | 5.96 |
Price to Sales | 2.42 | 2.55 | -24.65 % | |
Enterprise Value to EBITDA Multiple | 4.83 | 5.32 | -32.90 % |
NVO - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Excellent Score of 82.50
Piotroski F Score - Excellent Value of 8.0
Earning Yield of 14.98 %
Tremendous increasing trend in Net Profit for last 3 year
Excellent Net Margin for last 3 years
Over the last 3 years, the company has achieved Incredible Return on Equity
Over the last 3 years, the company has achieved Incredible Return on Assets
Excellent QoQ /QoQ FY EPS growth
Strong Return On Capital Employed of 65.46
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 95.22%
During the past twelve months, the company has given a strong Return On Asset of 30.91%
During the past twelve months, the company has given a strong Net Margin of 36.55%
All key Trailing Twelve Months Margin growing by 15 %
EBITDA is continuously increasing for last 3 Years
Steady Growth in EPS for last four quarters
Profitability Key Ratios
Ratio | TTM | Latest FY | Yoy Change | MRQ |
---|---|---|---|---|
Return On Equity | 95.22 | 78.53 | 18.08 % | 25.69 |
Return On Asset | 30.91 | 26.61 | 15.62 % | 8.50 |
Net Profit Margin | 36.55 | 36.03 | 14.82 % | 38.88 |
Operating Profit Margin | 45.03 | 40.00 | -5.39 % | 49.60 |
EBITDA Margin | 50.49 | 48.63 | 12.04 % | 54.06 |
Highlights
Market Cap | 587548 M |
Enterprise Value | 595610 M |
Price/Book TTM | 6.31 |
Outstanding Share | 4454.84 M |
Float/ Outstanding Share | 71.65% |
Dividend Yield | 1.03 % |
Share Holding
Guru Numbers
Price/Graham No | 1.28 |
Peter Lynch Ratio | 7.91 |
Piotroski F Score | 8.00 |
Altman Z Score | 3.87 |
Sloan Ratio | -0.072 |
Peter Lynch Fair Value | 337.39 |
NVO - Growth Highlights
Growth Analysis
Tremendous increasing trend in total sale last 3 year
Steady increase in Total Assets for last 3 Years
Growth Key Fields
Field | TTM | YoY Growth | QoQ Growth |
---|---|---|---|
Revenue | 244243 M | 31.26 % | 0.780 % |
Gross Profit | 206744 M | 32.32 % | 0.745 % |
EBITDA | 123307 M | 47.05 % | 23.91 % |
Net Profit | 89276.00 M | 50.71 % | 15.68 % |
EPS | 19.91 | 52.38 % | NA |
NVO - Stability Highlights
Stability Analysis
Tsr Stability Index - Good Score of 76.56
Altman Z Score of 3.89 suggests good Stability
Stability Key Ratios
Ratio | Latest FY | Yoy Change | MRQ |
---|---|---|---|
Debt to Equity Ratio | 0.211 | -20.90 % | 0.272 |
Cash Ratio | 0.178 | -8.59 % | |
Quick Ratio | 0.636 | -8.27 % | 0.500 |
Shareholders Equity | 33.88 | -2.08 % | |
Debt to EBITDA | 0.199 | -31.35 % |
Historical Valuation Ratios of Novo Nordisk A/S
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Novo Nordisk A/S
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Novo Nordisk A/S
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Novo Nordisk A/S
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)